Our aim is to provide affordable medicines that will improve patient access to necessary therapies
We seek to have a portfolio of credible brands, first-to-market products and deliver differentiated products to doctors and patients. Many of our brands hold significant market shares in the molecule and therapy areas where they are present. Branded generics is one of our biggest businesses operating in India and Emerging Markets around the world. Our branded products are accessible in over 40 countries, spanning regions such as Russia, Brazil, China, Central and Latin America, as well as the Association of Southeast Asian Nations (ASEAN), South and North Africa. We continue to accelerate access to affordable medicines with every product launch.
INDIA BUSINESS
India is a strong focus area for us. In the last few years, India business has contributed an increased share to our overall business. Our market rank was 10th as per Moving quarterly total (MQT) and 11th as per Moving Annual Total (MAT) in terms of sales value in March 2024. We aspire to break into the top 5 in India. Building and maintaining big brands, strong product launch momentum, dedicated R&D for differentiated products, strengthening our position in key and high-growth segments, and strategic inorganic opportunities will be key pillars to achieving this aspiration. We continue to drive our productivity enhancement in the field, tapping into digital and omni-channel marketing and other mediums.
We have established a leading presence in therapy areas such as oncology, gastroenterology, allergy, diabetics, pain management, among others. We became the 2nd largest vaccines player in India, through an exclusive partnership with Sanofi to distribute their vaccine brands in India. We launched drug-free migraine management device, Nerivio®, our first digital therapeutic product in India. We forayed into trade generics to increase our participation in the retail pharmaceutical market. We entered into a licensing agreement with U.S.-based biopharma, Pharmazz, to market first-in-class Centhaquine (Lyfaquin®) for treatment of hypovolemic shock in India. We partnered with Bayer to distribute the second brand for heart failure management drug, Vericiguat, in India and partnered with Jiangsu Hengrui Pharmaceuticals Co. Ltd. to promote its oral breast cancer NCE, Pyrotinib, in India. We entered into an exclusive licence agreement with Wellington Zhaotai Therapies Limited to develop and commercialise a Chimeric antigen receptor - T (CAR-T) cell therapy asset, ‘WL-002’ in India. The CAR-T asset ‘DRL-1801’ was approved for clinical trial in India. We launched 13 new brands in India.
We look forward to our India business continuing to be a key growth driver for us and contributing to our goal of serving over 1.5 billion patients by 2030.
EMERGING MARKETS
The Emerging Markets business is working to make our products available in new markets. Our focus is to improve the market share in the chosen therapy areas through growth in the existing products as well as new product launches, supported by sales and marketing excellence. Our medium-term strategy for the segment is to build a healthy portfolio pipeline, including oncology products, coupled with the expansion of biosimilars. We will continue to focus on building big brands and winning in chosen therapy areas through differentiated portfolio. We will further scale up in our major markets, which include Russia, China, Brazil, and South Africa and add new geographies by leveraging our in-house global portfolio of generics and biosimilars and seeking in-licensing opportunities. In the long term, our focus will be on introducing innovative products (sourced externally or developed in-house) to branded markets—such as Novel Assets like NCE/NBEs and Digital Therapeutics—and driving consumer innovation in OTC, Wellness, and Nutrition sectors.
We have our presence in Russia for over 30 years and it is a key market for us. IQVIA ranked us 15th in terms of sales in Russia on March 31, 2024. This was driven by improved existing business performance, launch of new products during the year along with divestment of some non-core brands. For the sixth year in a row, 6 of our leading products were voted as the ‘Product of the Year 2023’ in the popular choice category – reaffirming the trust that the people of Russia have in them.
We were among the earliest Indian pharma companies to have a business presence in China. We have a representative office that focuses on filings and approvals, and participation in procurement by Group Purchasing Organisation (GPO). Our joint venture entity (Kunshan Rotam Reddy Pharmaceutical Co. Ltd) offers a portfolio of niche and essential products, strengthening our presence in China.
In Latin America we have a strong presence in Brazil and Colombia. In just a little over seven years in Brazil, our team has established itself in the region with our diverse portfolio. Our primary focus in Brazil is oncology and institutional.
Recently, we have expanded our presence in Central America across 9 countries and countries neighbouring Chile. In 2024, we inaugurated our new office and warehouse in Jamaica.
We were recognised as ‘Company of the Year – Americas’ for the second year in a row at the Global Generics & Biosimilars Awards 2023! Our teams in China, Brazil, Colombia, Malaysia and Thailand have earned the Great Place to Work certification. Our team in Russia won the HeadHunter’s Best Employer Ranking in 2023. In South Africa, we were recognised as the Top Employer 2024. These certifications are a recognition of our work culture and environment, and of the employer brand that we have created. We believe in setting up our people for success with progressive people practices, empowering them to lead from the front and equipping them with the right skills to be efficient and effective.
With the aim of reaching more and more patients around the world, we are harnessing our deep science capabilities to create a robust portfolio in the region to become the partner of choice. As the need, scope and standards of healthcare evolve, we keep track of emerging needs to contribute to patient welfare. After all, Good Health Can’t Wait.
For more information, please visit our country sites:
India
Australia
Austria
Brazil
Chile
China
Columbia
New Zealand
Romania
Russia
South Africa
Ukraine
